The 36th Annual Healthcare Conference will be held in New York, December 3-5, 2024ROCKVILLE, Md., Nov. 21, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB, the "Company"), a U.S.-based global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024.Piper Sandler 36th Annual Healthcare Conference Presentation Details Presentati ...

Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025 Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024 Estimated cash runway into 2027, based on $184.4 million in cash and cash equivalents, and short-term investments as of September 30, 2024ROCKVILLE, Md., Nov. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global bio ...

文章核心观点 - I-Mab公司任命Sean (Xi-Yong) Fu博士为新任首席执行官 [1][2] - Fu博士拥有20多年生物医药行业经验,曾在默克公司工作15年,并创办过RVAC Medicines公司 [2] - I-Mab公司专注于开发创新免疫治疗药物,在美国马里兰州和新泽西州设有运营中心 [3] 公司概况 - I-Mab是一家总部位于美国的全球生物技术公司,专注于开发创新免疫治疗药物用于治疗癌症 [3] - 公司在马里兰州罗克维尔和新泽西州肖特希尔斯设有运营中心 [3] 新任CEO简介 - Sean (Xi-Yong) Fu博士被任命为I-Mab公司新任首席执行官,自2024年7月15日起担任临时CEO,现正式获任 [1][2] - Fu博士拥有20多年生物医药行业经验,曾在默克公司工作15年,负责涉及研发、业务发展、财务和运营管理等多个领域 [2] - 此前Fu博士还创办了RVAC Medicines公司,并担任ABio-X投资平台的运营合伙人 [2] - Fu博士拥有材料科学与工程博士学位,以及宾夕法尼亚大学沃顿商学院的MBA学位 [2] 公司未来发展 - 新任CEO Fu博士表示将与公司团队和合作伙伴共同努力,发挥公司产品组合的全部潜力,为癌症患者带来新的治疗方案 [2] - 公司目前有3个临床项目正在推进,未来将迎来重要里程碑 [2]

ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern Time.The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to ...

ROCKVILLE, Md., Oct. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will participate in one-on-one and small group meetings with investors at the Truist Securities BioPharma Symposium on November 7, 2024. Event Details Meeting Date Thursday, November 7, 2024 Meetings One-on-one and small group meetings: November 7, 2024 Sean Fu, PhD ...

I-Mab Sponsored ADR (IMAB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing earning ...

Expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody immunostimulant, shows promising single-agent activity in heavily pre-treated patients with gastric cancers expressing Claudin 18.2 at low and high levelsThe recommended Phase 2 dose for givastomig was determined to be 8-12 mg/kg; givastomig was well tolerated up to the highest study dosesA Phase 1b study, evaluating givastomig in combination with standard-of-care treatment (nivolumab + chemotherapy (FOLFOX)) in fro ...

- Pharmacokinetic/pharmacodynamic (PK/PD) modeling data from three Phase 1 studies providing dosing support for upcoming clinical trials- Exposure-Response (E-R) Analysis showed a positive correlation between uliledlimab concentration and ORR probability in mNSCLC patients- Randomized Phase 2 study of uliledlimab in combination with pembrolizumab plus chemotherapy expected to begin in 1H 2025ROCKVILLE, Md., Sept. 10, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech com ...

财务数据和关键指标变化 - 公司现金及现金等价物和短期投资为2.075亿美元(截至2024年6月30日) [53] - 公司预计根据目前的运营计划,现金储备将持续到2027年,包括几个重要的临床里程碑 [56] - 公司已发行在外的普通股相当于81.4百万美国存托凭证 [57] 各条业务线数据和关键指标变化 - 公司已将两项III期临床试验(felzartamab和eftansomatropin alfa)转移给TJ Bio [50] - 公司正在推进uliledlimab进入II期临床试验,并继续推进givastomig的I期临床试验 [50] 各个市场数据和关键指标变化 - 无相关内容 公司战略和发展方向及行业竞争 - 公司已完成从中国业务的剥离,成为一家总部位于美国的全球生物科技公司 [17][60] - 公司建立了一支经验丰富的美国管理团队,包括新任首席医疗官Phillip Dennis和首席财务官Joseph Skelton [19][20] - 公司正积极寻求通过外部合作或许可机会来进一步丰富管线,重点关注临床阶段的资产 [79] 管理层对经营环境和未来前景的评论 - 公司对自身的差异化管线、经验丰富的领导团队和充足的现金储备感到乐观,相信能在2024年下半年及以后取得重大进展 [60][62] 其他重要信息 - 公司已完成200百万美元赎回义务的消除,预计将在今年9月消除剩余约15百万美元的义务 [49] - 公司已完成从中国业务的剥离,并于4月2日宣布该交易 [17] - 公司已聘请PWCUS担任财务审计师 [52] - 公司已将员工人数从年底的220人精简至6月30日的34人 [52] 问答环节重要的提问和回答 问题1 **Joe Catanzaro 提问** 对于givastomig即将在ESMO 2024发布的临床数据,公司对于患者人数和新的发现有何预期? [66] 公司如何看待givastomig相比克劳丁18.2靶向ADC疗法的差异化? [67] **Phillip Dennis 回答** 公司将在ESMO 2024发布约30例胃癌患者的剂量扩展队列数据,数据将再次显示givastomig具有良好的安全性和可喜的客观缓解率。公司认为givastomig的耐受性使其更适合与前线标准治疗(如Folfox)联合,这是其相比ADC疗法的一大差异。[69][70] 问题2 **Unknown Analyst 提问** 公司完成向美国审计师过渡的目标时间是什么?未来费用在美国和中国的分配情况如何? [75] 公司在管线拓展方面,是否仍将重点放在肿瘤领域,还是考虑拓展到其他治疗领域? [75] **Sean Fu 回答** 公司已完成向PWCUS的过渡,PWCUS现已成为公司的审计师。随着剥离中国业务等一系列公司发展,未来的现金消耗将明显低于今年前两个季度,因为公司已精简组织架构,将重点放在临床项目开发上。[78] 公司正积极寻求通过外部合作或许可来进一步丰富管线,虽然目前管线都集中在肿瘤领域,但公司并不局限于此,也会关注相邻治疗领域的机会,只要是临床阶段的资产都在考虑范围之内。[79] 问题3 **Andres Maldonado 提问** 对于uliledlimab联合疗法的II期临床试验,公司在疗效方面需要达到什么标准才能推进?公司会参考哪些外部信号作为决策依据? [84] 公司如何利用TJ Bio即将在2025年下半年公布的II期PFS数据? [85] **Phillip Dennis 回答** 公司希望uliledlimab联合疗法的II期试验能在客观缓解率、无进展生存期等方面取得与Keynote 189方案相比有临床意义的改善,尤其是在高CD73表达患者群体中。[88] 公司密切关注其他CD73靶向疗法的临床进展,因为这些数据将有助于验证腺苷通路的重要性,增强公司对uliledlimab的信心。公司希望自身的II期试验以及TJ Bio的双联疗法试验(针对CD73高表达人群)能进一步支持公司的假说。[89]

Completed divestiture of China operationsUliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody)Clinical collaboration and supply agreement with Bristol Myers Squibb strengthens givastomig first-line gastric cancer combination studies (CLDN18.2 X 4-1BB bispecific)Ragistomig presentation at ASCO 2024 highlights encouraging early data (PD-L1 X 4-1BB bispecific)Well-positioned for pipeline advancement with $207.5 million in cash and cash equivalents, and short- ...